FibroGen Dirección

Dirección controles de criterios 2/4

El CEO de FibroGen's es Thane Wettig , nombrado en Jul 2023, tiene una permanencia de menos de un año. compensación anual total es $3.12M, compuesta por 17.1% salario y 82.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.16% de las acciones de la empresa, por valor de MX$2.68M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 5.3 años, respectivamente.

Información clave

Thane Wettig

Chief Executive Officer (CEO)

US$3.6m

Compensación total

Porcentaje del salario del CEO	15.7%
Permanencia del CEO	less than a year
Participación del CEO	0.2%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	5.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thane Wettig en comparación con los beneficios de FibroGen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$240m
Dec 31 2023	US$4m	US$573k	-US$284m
Sep 30 2023	n/a	n/a	-US$294m
Jun 30 2023	n/a	n/a	-US$322m
Mar 31 2023	n/a	n/a	-US$307m
Dec 31 2022	US$3m	US$535k	-US$294m
Sep 30 2022	n/a	n/a	-US$362m
Jun 30 2022	n/a	n/a	-US$220m
Mar 31 2022	n/a	n/a	-US$281m
Dec 31 2021	US$3m	US$510k	-US$290m
Sep 30 2021	n/a	n/a	-US$215m
Jun 30 2021	n/a	n/a	-US$231m
Mar 31 2021	n/a	n/a	-US$183m
Dec 31 2020	US$4m	US$263k	-US$189m

Compensación vs. Mercado: La compensación total de Thane($USD3.12M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD197.06K).

Compensación vs. Ingresos: La compensación de Thane ha aumentado mientras la empresa no es rentable.

CEO

Thane Wettig (58 yo)

less than a year

Permanencia

US$3,640,829

Compensación

Mr. Thane Wettig serves as Director of FibroGen, Inc. since October 2, 2023. He serves as Chief Executive Officer at FibroGen, Inc. since October 2, 2023 and served as Interim Chief Executive Officer since...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thane Wettig	CEO & Director	less than a year	US$3.64m	0.19% $ 3.6m
Juan Graham	Senior VP & CFO	2.7yrs	US$3.09m	0.049% $ 941.3k
Christine Chung	Senior Vice President of China Operations	17.3yrs	US$3.11m	0.21% $ 4.0m
Barry Berkowitz	Founder	29.3yrs	sin datos	sin datos
John Hunter	Chief Scientific Officer	2.8yrs	sin datos	sin datos
David DeLucia	Vice President of Corporate FP&A and Investor Relations	no data	sin datos	sin datos
Michael Lowenstein	Chief Legal Officer	8.1yrs	sin datos	sin datos
Tricia Stewart	Chief People Officer	3yrs	sin datos	sin datos
Kirk Christoffersen	Chief Business Officer	3.5yrs	sin datos	sin datos
Rahul Kaushik	Senior Vice President of Pharmaceutical Development	2.3yrs	sin datos	sin datos
Elizabeth Bearby	Senior VP of Regulatory	less than a year	sin datos	sin datos
Deyaa Adib	Senior VP & Chief Medical Officer	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de FGEN * se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thane Wettig	CEO & Director	less than a year	US$3.64m	0.19% $ 3.6m
Jeffrey Henderson	Independent Director	8.8yrs	US$370.53k	0.021% $ 400.7k
George Martin	Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Suzanne Blaug	Independent Director	4.9yrs	US$388.03k	0.021% $ 414.9k
Jeffrey Edwards	Independent Director	8.6yrs	US$385.53k	0.026% $ 500.1k
James Schoeneck	Independent Chairman of the Board	14.1yrs	US$499.58k	0.082% $ 1.6m
Gerald Lema	Independent Director	6.7yrs	US$383.03k	0.037% $ 721.8k
Maykin Ho	Independent Director	5.4yrs	US$375.53k	0.023% $ 451.8k
Benjamin Cravatt	Independent Director	3.8yrs	US$392.55k	0.021% $ 398.0k
Aoife Brennan	Independent Director	3.8yrs	US$373.03k	0.020% $ 382.7k

5.4yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de FGEN * se considera experimentada (5.3 años de antigüedad promedio).

FibroGen Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

CEO & Director recently bought Mex$1.6m worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Insufficient new directors

Insufficient new directors

Recent updates

First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.81 loss in 1Q 2023)

Insufficient new directors

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Insufficient new directors

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

CEO & Director recently bought Mex$1.6m worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings released: US$2.92 loss per share (vs US$3.14 loss in FY 2022)

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Insufficient new directors

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Insufficient new directors

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings released: US$0.90 loss per share (vs US$0.78 loss in 2Q 2022)

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Insider recently sold Mex$2.2m worth of stock

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

CEO & Director recently sold Mex$589k worth of stock

CEO & Director recently sold Mex$589k worth of stock

Executive VP & Chief Commercial Officer recently sold Mex$225k worth of stock

Third quarter 2022 earnings released: US$0.98 loss per share (vs US$0.54 profit in 3Q 2021)

FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes

Second quarter 2022 earnings released: US$0.78 loss per share (vs US$1.45 loss in 2Q 2021)

FibroGen, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Fibrogen Announces Completion of Patient Enrollment in LELANTOS-2, A Phase 3 Clinical Study of pamrevlumab in Duchenne Muscular Dystrophy

FibroGen, Inc., Annual General Meeting, Jun 16, 2022

FibroGen, Inc. to Report Q1, 2022 Results on May 09, 2022

FibroGen, Inc. Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

FibroGen, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.36 in 3Q 2020)

Independent Director recently sold Mex$3.0m worth of stock

Chief Commercial Officer recently bought Mex$727k worth of stock

FibroGen, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Astellas Receives EC Approval for First-Inclass Evrenzo (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Second quarter 2021 earnings released: US$1.45 loss per share (vs US$0.95 loss in 2Q 2020)

FibroGen, Inc. Announces Outcome of FDA Advisory Committee Review of Roxadustat

Independent Director Kalevi Kurkijärvi has left the company

Astellas Receives Positive CHMP Opinion for Evrenzo™ (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

Scott+Scott Attorneys At Law LLP Reminds Investors of Securities Class Action Against Fibrogen, Inc

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.78 loss per share (vs US$0.89 loss in 1Q 2020)

The Schall Law Firm and Roche Freedman LLP Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Fibrogen, Inc

Rosen Law Firm Announces the Filing of a Class Action Lawsuit on Behalf of Purchasers of the Securities of FibroGen, Inc

FibroGen, Inc. Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

Executive Advisor to Chief Executive Officer K. Yu has left the company

Full year 2020 earnings released: US$2.11 loss per share (vs US$0.89 loss in FY 2019)

Revenue misses expectations

FibroGen, Inc. to Report Q4, 2020 Results on Mar 01, 2021

FibroGen, Inc. Enters into Supply Agreement with Astellas Pharma Europe Ltd

FibroGen, Inc. Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

FibroGen, Inc. Provides Regulatory Update on Roxadustat

Fibrogen, Inc. Announces Appointment of Mark Eisner as Incoming Chief Medical Officer

Astellas and FibroGen Receive Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis